Deciphera Pharmaceuticals, Inc. (DCPH)
收市後：
| 前收市價 | 25.27 |
| 開市 | 25.30 |
| 買盤 | 25.33 x 200 |
| 賣出價 | 25.39 x 100 |
| 今日波幅 | 25.27 - 25.40 |
| 52 週波幅 | 9.90 - 25.40 |
| 成交量 | |
| 平均成交量 | 1,491,780 |
| 市值 | 2.085B |
| Beta 值 (5 年，每月) | 0.39 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.29 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 26.38 |
- Reuters
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
BenzingaWhy Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to QINLOCK – Deciphera’s switch-control inhibitor for the treatment of fourth-li
Barrons.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72%
Deciphera Pharmaceuticals is being bought by Japan’s ONO Pharmaceutical in a deal valued at $2.4 billion.
